FDA Approves New Immunotherapy Combo for MelanomaNivolumab plus relatlimab might be a new standard of care. FDA Approvalsadminmarzo 19, 2022Uncategorized Nivolumab plus relatlimab might be a new standard of care. FDA Approvals
